Making the COVID-19 Oral Treatment: How 2,000+ Pfizer Team Members Made It Happen
As the potential threat of COVID-19 became clear by early 2020, teams across Pfizer sprang into action. Together, they worked to better understand the novel virus.
adults, which suggest that BNT162b2 triggers the production of neutralizing receptor binding domain (RBD)-binding IgG concentrations and SARS-CoV-2 …
as measured by RBD-binding IgG concentrations and SARS-CoV-2 …
fully human anti-PD-L1 IgG1 monoclonal antibody. By …
However, the induction of anti-OspA IgG (anti-outer surface protein A …
antibodies called “immunoglobulins” (IgG) in the blood which help protect …
adults, which suggest that BNT162b2 triggers the production of neutralizing with prespecified serotype-specific IgG concentrations and IgG Geometric …
fully human anti-PD-L1 IgG1 monoclonal antibody. By …
fully human anti-PD-L1 IgG1 monoclonal antibody. By …
titers and RBD-binding IgG concentrations after the second …
fully human anti-PD-L1 IgG1 monoclonal antibody. By …
Behind the Science Features
Press Releases
05.10.2022
05.06.2022
05.04.2022
05.04.2022
05.03.2022
04.29.2022
04.29.2022
04.28.2022
04.28.2022
04.28.2022
04.28.2022
04.27.2022
Media Resources
This information is intended for media professionals. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Clinical Trials
Our Careers